跳至主要内容
临床试验/KCT0007355
KCT0007355
尚未招募
未知

Exploring Brain Changes in Patients with Heart Failure with Reduced Ejection Fraction DuringVulnerable Period.

Koera University Guro Hospital0 个研究点目标入组 30 人待定

概览

阶段
未知
干预措施
未指定
疾病 / 适应症
Diseases of the circulatory system
发起方
Koera University Guro Hospital
入组人数
30
状态
尚未招募
最后更新
3年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
3年前
研究类型
Observational Study
性别
All

研究者

发起方
Koera University Guro Hospital

入排标准

入选标准

  • 1\. Patient with left ventricular ejection fraction of 40% or less on echocardiogram within 3 months.
  • 2\. Patient with sinus rhythm without atrial fibrillation.
  • 3\. Patient who have experienced worsening heart failure within 4 weeks or have been newly diagnosed with heart failure.
  • 1\) Symptoms above NYHA II
  • 2\) NT\-proBNP 800 \= pg/mL
  • 4\. Patient who can take a brain MRI without assistance.

排除标准

  • 1\. Patient who has been diagnosed with atrial fibrillation or is being treated.
  • 2\. Patient who had a stroke or cerebral hemorrhage within 3 months of participation in the study.
  • 3\. Patient who has a myocardial infarction or needs surgery or vascular intervention for coronary artery disease at the time of participation in the study.
  • 4\. Patient who are taking more than one anti\-platelet drug at the time of participation in the study. (COX\-1 inhibitor such as aspirin, triflusal, ADP receptor antagonists such as clopidogrel, ticlopidine, prasugrel, ticagrelor. PDE\-3 inhibitor such as cilostazol, dipyridamole. serotonin receptor antagonists such as sarpogrelate.)
  • 5\. Patient who are taking anticoagulation drug or need anticoagulation (e.g. mechanical valves, moderate to severe mitral stenosis, pulmonary thromboembolism or deep vein thrombosis.)
  • 6\. Patient with terminal heart failure expected to die within 6 months
  • 7\. Patient who is a bed\-ridden state or cannot take a brain MRI without help.
  • 8\. Patient who have already been diagnosed with dementia and are taking drugs such as donepezil, galantamine and rivastigmine.

结局指标

主要结局

未指定

相似试验